Glycoprotein News and Research

RSS

SARS-CoV-2 antibodies in breast milk: Study

A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.

26 Jul 2021

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

Iain Chapple, University of Birmingham, England, presented the oral session "Longitudinal Serological and Vaccination Responses to SARS-COV-2 in Dental Professionals" at the virtual 99th General Session & Exhibition of the International Association for Dental Research (IADR), held in conjunction with the 50th Annual Meeting of the American Association for Dental Research (AADR) and the 45th Annual Meeting of the Canadian Association for Dental Research (CADR), on July 21-24, 2021.

23 Jul 2021

Injecting mice with pulmonary endothelial cells can reverse symptoms of emphysema

Researchers at Weill Cornell Medicine and NewYork-Presbyterian in New York have discovered that injecting mice with pulmonary endothelial cells-the cells that line the walls of blood vessels in the lung-can reverse the symptoms of emphysema.

21 Jul 2021

Potent nasal vaccine protects non-human primates from SARS-CoV-2

A team of US-based scientists has recently demonstrated the efficacy of a live attenuated, recombinant coronavirus disease 2019 (COVID-19) vaccine candidate currently under phase I clinical trial as a single-dose intranasal vaccine.

20 Jul 2021

New research may offer clues to why MS patients develop progressive disability

Did you know multiple sclerosis (MS) means multiple scars? New research shows that the brain and spinal cord scars in people with MS may offer clues to why they developprogressive disability but those with related diseases where the immune system attacks the central nervous system do not.

19 Jul 2021

Researchers conduct molecular dynamic study of SARS-CoV-2 spike glycoprotein and human skin model interactions

Currently, there is a lack of understanding of the physico-chemical features of the interaction between coronaviruses and different surfaces. However, new research has been published on the bioRxiv* preprint server that documents the molecular details of the interaction between the human skin and SARS-CoV-2.

19 Jul 2021

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

In a recent study by US researchers (currently available on the medRxiv* preprint server), a specific immunoassay based on the spike glycoprotein’s receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only well suited for the detection of antibody response after infection and vaccination but may also represent a method of choice when conducting seroepidemiological studies.

19 Jul 2021

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

A short report recently published in the Journal of Infectious Diseases demonstrates how spike mutations L452R and E484Q found in the variant B.1.617.1 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) each confer modestly diminished sensitivity to Pfizer-BioNTech (BNT162b2) mRNA vaccine-elicited antibodies – with combined mutations having a similar impact as either one of them alone.

19 Jul 2021

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Multivalent protein-based minibinders hold great promise as potential prophylactic and treatment agents, as they can retain their activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. This was revealed in a recent tour-de-force research study currently available on the bioRxiv* preprint server while the article undergoes the peer review process.

11 Jul 2021

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

Researchers in the United States have shown that targeting the N-terminal domain (NTD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike protein could achieve broad neutralization of variants of concern.

11 Jul 2021

SARS-CoV-2 immunity due to prior infection or vaccination is similar, study says

A new study finds that the rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection is low following one episode of the infection.

11 Jul 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Growing concern over SARS-CoV-2 Lambda variant

A new report from Chile – currently available on the medRxiv* preprint server – reveals how mutations in the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Lambda variant can confer protection from neutralizing antibodies and increase viral infectivity rates, which means massive vaccination campaigns should be accompanied by strict genomic surveillance.

8 Jul 2021

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

A new paper discusses an intriguing new mechanism of immune evasion traceable to specific mutations in the B.1.427/B.1.429 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7 Jul 2021

Research shows how loss of de-N-glycosylation enzyme causes detrimental effects

Peptide: N-glycanase (NGLY1) is an evolutionarily conserved enzyme for removing N-linked glycans (N-glycans) from glycoproteins and is involved in proteostasis of N-glycoproteins in the cytosol. In 2012, a rare genetic disorder called NGLY1 deficiency was discovered by an exome analysis.

7 Jul 2021

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.

7 Jul 2021

Mutations in the Epsilon variant contribute to SARS-CoV-2 immune evasion

Three mutations in the Epsilon coronavirus spike protein dampen the neutralizing potency of antibodies induced by current vaccines or past COVID infections.

6 Jul 2021

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

A recent tour-de-force study by researchers from the United Kingdom reveals variants of the human angiotensin-converting enzyme 2 (ACE2) that can improve or decrease binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – including two variants with distinct population distributions showing an enhanced affinity for viral spike glycoprotein.

5 Jul 2021

Varenicline blocks SARS-CoV-2 infection in cells and animal models

A new paper released on the bioRxiv* preprint server suggests that the nicotinic acetylcholine receptor (nACHR) agonist, varenicline tartrate, has antiviral activity against the virus.

5 Jul 2021

Glycoprotein News and Research

SARS-CoV-2 antibodies in breast milk: Study

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

Injecting mice with pulmonary endothelial cells can reverse symptoms of emphysema

Potent nasal vaccine protects non-human primates from SARS-CoV-2

New research may offer clues to why MS patients develop progressive disability

Researchers conduct molecular dynamic study of SARS-CoV-2 spike glycoprotein and human skin model interactions

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

SARS-CoV-2 immunity due to prior infection or vaccination is similar, study says

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

Growing concern over SARS-CoV-2 Lambda variant

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

Research shows how loss of de-N-glycosylation enzyme causes detrimental effects

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

Mutations in the Epsilon variant contribute to SARS-CoV-2 immune evasion

Study explores how human ACE2 variants can modify SARS-CoV-2 binding

Varenicline blocks SARS-CoV-2 infection in cells and animal models

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News